Navigating the Complexity of Gene Therapy

Many cell and gene therapies can prove difficult for reimbursement due to their high cost and complicated risk-to-benefit ratio. When that therapy is a lifesaving medication, it makes the issue of patient access paramount.

In the latest case study from UBC, we discuss how our patient access team worked incredibly closely with the sponsor to create a program tailored to this unique pediatric population and therapy. This spinal muscular atrophy (SMA) gene therapy provided unique challenges for our case managers. Find out how our team overcame:

• A complex manufacturing and distribution channel
• Uncertain payer coverage for a high-cost product
• FDA requirements for a pre-treatment companion diagnostic
• Coordinating and communicating with almost a dozen closely involved stakeholders

Download the case study today using the form to the right.